No volume effect on retrograde colonic spread of rectally-administered ropivacaine gel

Alimentary Pharmacology and Therapeutics

Volumn 18, Issue 6, 2003, Pages 655-660

  Arlander, E ^a,b,d   Cederlund, T ^b   Mare K ^c  

^a ASTRAZENECA R AND D   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYPROPYLMETHYLCELLULOSE; PENTETATE TECHNETIUM TC 99M; ROPIVACAINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DESCENDING COLON; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG FORMULATION; DRUG TOLERABILITY; GAMMA SCINTIGRAPHY; GEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; VISCOSITY;

EID: 0141650536     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01741.x     Document Type: Article

References (24)

1. Mutlu EA, Farhadi A, Keshavarzian A. New developments in the treatment of inflammatory bowel disease. Expert Opinion Inv Drugs 2002; 11: 365-85.
2. Bjorck S, Dahlstrom A, Johansson L, Ahlman H. Treatment of the mucosa with local anaesthetics in ulcerative colitis. Agents Actions 1992: Special no. C60-72.
3. Bjorck S, Dahlstrom A, Ahlman H. Topical treatment of ulcerative proctitis with lidocaine. Scand J Gastroenterol 1989; 24: 1061-72.
4. McClure JH, Ropivacaine. Br J Anaesth 1996; 76: 300-7.
5. Martinsson T, Oda T, Fernvik E, Roempke K, Dalsgaard CJ, Svensjo E. Ropivacaine inhibits leukocyte rolling, adhesion and CD11b/CD18 expression. J Pharm Exp Ther 1997; 283: 59-65.
6. Martinsson T, Ljung T, Rubio C, Hellstrom PM. Beneficial effects of ropivacaine in rat experimental colitis. J Pharm Exp Ther 1999; 291: 642-7.
7. Martinsson T, Haegerstrand A, Dalsgaard CJ. Effects of ropivacaine on eicosanoid release from human granulocytes and endothelial cells in vitro. Inflamm Res 1997; 46: 398-403.
8. Martinsson T. Ropivacaine inhibits serum-induced proliferation of colon adenocarcinoma cells in vitro. J Pharm Exp Ther 1999; 288: 660-4.
9. Arlander E, Ost A, Stahlberg D, Lofberg R. Ropivacaine gel in active distal ulcerative colitis and proctitis - a pharmacokinetic and exploratory clinical study. Aliment Pharmacol Ther 1996; 10: 73-81.
10. Bitton A. Medical management of ulcerative proctitis, proctosigmoiditis, and left-sided colitis. Semin GI Dis 2001; 12: 263-74.
11. Marshall JK, Irvine EJ. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol 2000; 95: 1628-36.
12. Ardizzone S, Porro GB. Comparative tolerability of therapies for ulcerative colitis. Drug Safety 2002; 25: 561-82.
13. Otten MH, De Haas G, Van den Ende R. Colonic spread of 5-ASA enemas in healthy individuals, with a comparison of their physical and chemical characteristics. Aliment Pharmacol Ther 1997; 11: 693-7.
14. van Bodegraven AA, Boer RO, Lourens J, Tuynman HA, Sindram JW. Distribution of mesalazine enemas in active and quiescent ulcerative colitis. Aliment Pharmacol Ther 1996; 10: 327-32.
15. Nyman-Pantelidis M, Nilsson A, Wagner ZG, Borga O. Pharmacokinetics and retrograde colonic spread of budesonide enemas in patients with distal ulcerative colitis. Aliment Pharmacol Ther 1994; 8: 617-22.
16. Campieri M, Paoluzi P, D'Albasio G, Brunetti G, Pera A, Barbara L. Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis. A multicenter comparative trial with 5-ASA enema. Dig Dis Sci 1993; 38: 1843-50.
17. Hardy JG, Perkins AC. Validity of the geometric mean correction in the quantification of whole bowel transit. Nucl Med Commun 1985; 6: 217-24.
18. Engman M, Neidenstrom P, Norsten-Hoog C, Wiklund SJ, Bondesson U, Arvidsson T. Determination of ropivacaine and [2H3]ropivacaine in biological samples by gas chromatography with nitrogen-phosphorus detection or mass spectrometry. J Chromatogr B 1998; 709: 57-67.
19. Brown J, Haines S, Wilding IR. Colonic spread of three rectally administered mesalazine (Pentasa) dosage forms in healthy volunteers as assessed by gamma scintigraphy. Aliment Pharmacol Ther 1997; 11: 685-91.
20. Tiel-van Buul MM, Mulder CJ, van Royen EA, Wiltink EH, Tytgat GN. Retrograde spread of mesalazine (5-aminosalicylic acid)-containing enema in patients with ulcerative colitis. Clin Pharmacokinet 1991; 20: 247-51.
21. Kruis W, Bull U, Eisenburg J, Paumgartner G. Retrograde colonic spread of sulphasalazine enemas. Scand J Gastroenterol 1982; 17: 933-8.
22. Campieri M, Lanfranchi GA, Brignola C, et al. Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis. Dis Colon Rectum 1986; 29: 108-10.
23. Gionchetti P, Venturi A, Rizzello F, et al. Retrograde colonic spread of a new mesalazine rectal enema in patients with distal ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 679-84.
24. Arlander E, Sjovall J, Sorstad J, Norsten-Hoog C, Gustafsson LL. Rectal ropivacaine is absorbed proportionally to the dose. with low intraindividual variability. Br J Clin Pharmacol 2003; 55: 14-22.